Literature DB >> 2517951

MHC class I expression on human tumour cells and their susceptibility to NK lysis.

J Pena1, R Solana, M C Alonso, M Santamaria, R Serrano, R Ramirez, J Carracedo.   

Abstract

Although natural killer (NK) activity is not restricted by the major histocompatibility complex (MHC), it has been suggested that the level of expression of MHC antigens by target cells may influence their lysis by NK cells. We have studied the NK susceptibility of 20 cell lines obtained from primitive and metastatic human tumours and the K562 cell line treated with gamma-interferon, phorbol ester TPA and tumour factor NK-RIF. When the levels of MHC class I antigen expression on the human tumour cell lines and their NK susceptibility were compared, no relationship between these two parameters was observed. Furthermore the treatment of K562 with either gamma-interferon, TPA or NK-RIF decreased its NK susceptibility independently of MHC class I expression. These results indicate that the MHC class I antigen is not the only factor directly involved in NK susceptibility and suggest that other membrane structures modulated by gamma-interferon, TPA or NK-RIF may also influence NK susceptibility.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517951     DOI: 10.1111/j.1744-313x.1989.tb00488.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  3 in total

Review 1.  Histocompatibility antigens and natural killer susceptibility.

Authors:  J Peña; R Solana
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing.

Authors:  A M Nouri; R F Hussain; A V Dos Santos; M Mansouri; R T Oliver
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

3.  Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF).

Authors:  M Marubayashi; R Solana; R Ramirez; E Aranda; F Galan; J Peña
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.